OmniComm’s TrialMaster® EDC Selected for Multi-Study Cancer Research

November 27, 2018

Applied Clinical Trials

An international biopharmaceutical company has signed a multiyear agreement with OmniComm Systems, Inc. in which the company will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple research sites to test a cancer treatment.

Read the full release here.

Related Content:

News